(MedPage Today) — HOUSTON — Survival in untreated, intermediate- and higher-risk myelodysplastic syndromes (MDS) failed to improve with the addition of the targeted agent venetoclax (Venclexta) to chemotherapy, a large randomized trial showed…
Source link : https://www.medpagetoday.com/meetingcoverage/soho/117342
Author :
Publish date : 2025-09-06 17:16:00
Copyright for syndicated content belongs to the linked Source.
